Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation: A Cohort of 112 Patients
Introduction. Recent trials demonstrated clinically significant benefits in HER2-nonamplified breast cancer with HER2-low expression using novel anti-HER2 antibody-drug conjugates. Thus, HER2-low breast cancer was proposed as a separate diagnostic entity. Herein, we reclassify HER2-negative cancers...
Saved in:
| Main Authors: | Gokce Deniz Ardor, Miglena K. Komforti, Helena Hanna, Onur Ibanoglu, Abigail Lochala, Aziza Nassar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | The Breast Journal |
| Online Access: | http://dx.doi.org/10.1155/2023/9725647 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Interobserver variability in her2 immunohistochemistry analysis and its clinical implications with the advent of the HER2-low category
by: Ana Catharina Joaquim, et al.
Published: (2025-08-01) -
Genetic Alterations in HER2-Positive and Equivocal Breast Cancer by Immunohistochemistry
by: Tsai YF, et al.
Published: (2025-03-01) -
Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff
by: Agata Wróbel, et al.
Published: (2025-04-01) -
Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer
by: Miaomiao Jia, et al.
Published: (2024-01-01) -
Fully automatic HER2 tissue segmentation for interpretable HER2 scoring
by: Mathias Öttl, et al.
Published: (2025-04-01)